Targeted Agents for Spinal Pain Localization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging modalities are inadequate for accurately and specifically identifying and localizing the sources of back pain, particularly in the lower lumbar region, as they often fail to correlate disc degeneration with pain, leading to ineffective treatment strategies.
Innovation Solution
A system utilizing targeted agents that differentially bind to pain factors at spinal joints, enabling enhanced diagnostic localization and selective tissue therapy through energy delivery, with options including nerve, blood vessel, and inflammatory cytokine markers, to identify and treat the source of back pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging modalities (CT or MRI) are used to identify disc anatomy, then disc degeneration can be detected, but the exact site of pain within or around the disc cannot be localized
Solution Approach 1:
The patent applies local quality by using targeted agents that specifically bind to pain factors at the exact location where pain is generated. Different regions of the disc can have different concentrations of pain factors (e.g., inflammatory cytokines, nerve growth factor), and the imaging agents reveal these local variations, allowing precise localization of pain sources rather than just showing general disc degeneration.
Solution Approach 2:
The patent uses targeted imaging agents as intermediaries that bind to pain factors. These agents serve as mediators between the pain factors (which are not directly visible) and the imaging system. The agents transfer the information about pain factor locations to the imaging modality, enabling visualization of specific pain sites that would otherwise be invisible to conventional imaging.
2Measurement precision
If targeted agents are used to enhance diagnostic localization and selective tissue therapy, then diagnostic accuracy and therapeutic precision are improved, but device complexity and treatment cost increase
Solution Approach 1:
The targeted imaging agents have multi-functionality, serving both diagnostic and therapeutic purposes. The same agent that binds to pain factors for imaging can also deliver therapeutic payloads (drugs, genes, or energy) to the same location. This dual function reduces the need for separate diagnostic and therapeutic systems, thereby limiting the increase in overall system complexity.
Solution Approach 2:
The system is segmented into modular components: the targeted agent (with its specific binding properties), the delivery mechanism (injection system or energy delivery device), and the imaging system. This segmentation allows each component to be optimized independently and facilitates integration with existing clinical infrastructure, managing complexity through modularity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise imaging and targeted therapy of pain sources, improving diagnostic accuracy and therapeutic outcomes for back pain by selectively differentiating pain factors at the site of injury within spinal joints.
Implementation Method 1
the targeted agent is characterized by differentially binding to a pain factor at a location of a spinal joint associated with a source of the back pain
Data Source
Figure 1
Figure 2A~2B
Figure 2C~2D
AI summary
Pain factors are labeled with targeted agents or markers delivered into the body. The labeled pain factors are imaged with appropriate imaging tools in a manner allowing selective identification and localization of areas of pain source or transmission. The labeled pain factors allow spatial differentiation in the imaging sufficient to specify the location of the pain so as to drive therapeutic decisions and techniques in order to treat the pain. Pain factors labeled and imaged in this manner may include one or more of nerve factors, blood vessel factors, cellular factors, and inflammation factors. Labeled markers may include for example radioactive materials (e.g. tritiated or iodinated molecules) or other materials such as metal (e.g. gold) nanoparticles. Intermediary binding materials may be used, such as for example bi-specific antibodies. Therapeutic components of the system and method include for example localized energy delivery or ablation treatments, or local drug or other chemical delivery. Locations containing pain factor selectively bound by targeted agents are selectively treated with directed energy into a region containing the targeted agent bound to the pain factor.